{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Group+Regimen&page=34", "query": { "intervention": "Control Group Regimen", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 969, "total_pages": 97, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Group+Regimen&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Group+Regimen&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T02:55:55.597Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00224406", "title": "Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ischemia-Reperfusion Injury", "Lung Transplantation" ], "interventions": [ { "name": "Repertaxin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Dompé Farmaceutici S.p.A", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 114, "start_date": "2005-05-01", "completion_date": "2007-09-13", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-10-27T02:55:55.597Z", "location_count": 5, "location_summary": "Los Angeles, California • Denver, Colorado • St Louis, Missouri + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00224406" }, { "nct_id": "NCT04488081", "title": "I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Remdesivir", "type": "DRUG" }, { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Cenicriviroc", "type": "DRUG" }, { "name": "Icatibant", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "dornase alfa", "type": "BIOLOGICAL" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" }, { "name": "IC14", "type": "BIOLOGICAL" }, { "name": "Aviptadil", "type": "DRUG" }, { "name": "narsoplimab", "type": "BIOLOGICAL" }, { "name": "Cyproheptadine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1500, "start_date": "2020-07-31", "completion_date": "2030-07-31", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-10-27T02:55:55.597Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Davis, California • Irvine, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Davis", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04488081" }, { "nct_id": "NCT06090097", "title": "Knee Biofeedback Rehabilitation Through Game Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Knee Osteoarthritis" ], "interventions": [ { "name": "KneeBRIGHT System", "type": "DEVICE" }, { "name": "Control Exercise", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Barron Associates, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "30 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2024-09-04", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-10-27T02:55:55.597Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06090097" }, { "nct_id": "NCT04851613", "title": "Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Afuresertib", "type": "DRUG" }, { "name": "Afuresertib/placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Laekna Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2022-02-18", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-27T02:55:55.597Z", "location_count": 6, "location_summary": "Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 3 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT04851613" }, { "nct_id": "NCT04071951", "title": "Pharmacist Intervention to Reduce Post-Hospitalization Utilization", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Nonadherence, Patient", "Polypharmacy", "Readmission" ], "interventions": [ { "name": "Pharmacist-led Hospital Discharge Care Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 6478, "start_date": "2019-12-23", "completion_date": "2027-01", "has_results": true, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-27T02:55:55.597Z", "location_count": 2, "location_summary": "Los Angeles, California • Boston, Massachusetts", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04071951" }, { "nct_id": "NCT02681796", "title": "Epidural Analgesia Use in Pancreatic Resections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer of Pancreas", "Cancer of the Pancreas", "Pancreas Cancer", "Pancreas Neoplasms", "Pancreatic Cancer" ], "interventions": [ { "name": "Bupivacaine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2016-06-07", "completion_date": "2020-02-07", "has_results": false, "last_update_posted_date": "2020-03-12", "last_synced_at": "2026-10-27T02:55:55.597Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02681796" }, { "nct_id": "NCT04681729", "title": "Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cold Urticaria" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Non sedating H1-antihistamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 82, "start_date": "2020-12-10", "completion_date": "2023-04-20", "has_results": true, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-10-27T02:55:55.597Z", "location_count": 5, "location_summary": "San Diego, California • Boise, Idaho • Owensboro, Kentucky + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Boise", "state": "Idaho" }, { "city": "Owensboro", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04681729" }, { "nct_id": "NCT04273282", "title": "A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cataract" ], "interventions": [ { "name": "Dexycu intracameral dexamethasone", "type": "DRUG" }, { "name": "Prednisolone Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Research Insight LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2019-12-16", "completion_date": "2020-11-24", "has_results": false, "last_update_posted_date": "2020-12-11", "last_synced_at": "2026-10-27T02:55:55.597Z", "location_count": 2, "location_summary": "Laguna Hills, California • Garden City, New York", "locations": [ { "city": "Laguna Hills", "state": "California" }, { "city": "Garden City", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04273282" }, { "nct_id": "NCT04315558", "title": "Revefenacin in Acute Respiratory Insufficiency in COPD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COPD", "Acute Respiratory Failure" ], "interventions": [ { "name": "Revefenacin Inhalation Solution [Yupelri]", "type": "DRUG" }, { "name": "Ipratropium Bromide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 21, "start_date": "2020-11-01", "completion_date": "2025-01-01", "has_results": true, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-27T02:55:55.597Z", "location_count": 2, "location_summary": "Los Angeles, California • Santa Monica, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04315558" }, { "nct_id": "NCT02848326", "title": "Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Migraine, With or Without Aura" ], "interventions": [ { "name": "Atogepant", "type": "DRUG" }, { "name": "Placebo-matching Atogepant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 834, "start_date": "2016-09-06", "completion_date": "2018-04-23", "has_results": true, "last_update_posted_date": "2018-12-06", "last_synced_at": "2026-10-27T02:55:55.597Z", "location_count": 75, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Carlsbad, California + 66 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Carlsbad", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02848326" } ] }